Drug intelligence / Profile preview

DWC202213

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical

Overview

DWC202213 is a drug candidate under clinical investigation by Daewoong Pharmaceutical. It is being studied in combination with DWP16001 as part of a fixed-dose combination (DWJ1563) for metabolic disorders, specifically type 2 diabetes mellitus. The primary focus of current trials is to compare the pharmacokinetic and safety profiles of the fixed-dose combination versus the loose combination of its components[4][5]. The mechanism of action for DWC202213 itself has not been publicly disclosed[2].

Beyond the preview

Go deeper on DWC202213.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202213.

Explore the full profile